AstraZeneca is a leading British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 by the merger of Sweden’s Astra AB and the UK’s Zeneca Group. Headquartered in Cambridge, UK, the firm is a research-driven powerhouse focusing on three core areas: Oncology, Cardiovascular, Renal & Metabolism (CVRM), and Respiratory & Immunology. Recently, it has expanded into Rare Diseases through the acquisition of Alexion. Renowned for blockbusters like Tagrisso and Farxiga, AstraZeneca aims to deliver life-changing medicines through innovation and precision medicine.
Here are some articles to give you a basic understanding of the company:
AstraZeneca – background and history
Below is a list of articles for the company:
-
AstraZeneca – FY25Q3 report
Here is the summary of AstraZeneca’s 9M and Q3 2025 results: Financial Highlights Therapy Area Performance (9M 2025) R&D and Strategic Updates FY 2025 Guidance AstraZeneca reiterated its full-year guidance at CER: Consolidated Income Statement Item 9M 2025 (Sm) % of Total Revenue YoY Change Product Sales 41,035 94.9% 9% Alliance Revenue 2,108 4.9% 41%…
-
AstraZeneca – History and Competitions
The history of AstraZeneca can be broken down into four distinct strategic phases: Phase 1: Foundations and Early Breakthroughs (1913-1998) Before the merger, both companies established themselves as research powerhouses in their respective regions. Core Strategy: Focus on fundamental scientific research in specific therapeutic areas, expanding from Nordic and British domestic markets to a global…